NuGen Medical Devices Inc. (TSXV:NGMD)
Canada · Delayed Price · Currency is CAD 0.0150
-0.0050 (-25.00%)
At close: Jul 29, 2026
NuGen Medical Devices Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.15 | 0.26 | 1.01 | 0.33 | 0.15 | 0.14 | |
Revenue Growth | -86.31% | -74.46% | 204.73% | 117.52% | 10.69% | 191.04% |
Cost of Revenue | 0.08 | 0.13 | 0.49 | 0.17 | 0.05 | 0.05 |
Gross Profit | 0.07 | 0.13 | 0.52 | 0.16 | 0.1 | 0.09 |
Selling, General & Admin | 4.12 | 3.66 | 5.03 | 7.52 | 4.24 | 5.26 |
Operating Expenses | 4.52 | 4.35 | 5.68 | 8.21 | 4.89 | 5.88 |
Operating Income | -4.45 | -4.22 | -5.16 | -8.05 | -4.79 | -5.79 |
Interest Expense | -3.5 | -3.06 | -1.67 | -1.24 | -1.01 | -1.21 |
Currency Exchange Gain (Loss) | 1.2 | -0.1 | -0.11 | -0.11 | -0.1 | 0.3 |
Other Non Operating Income (Expenses) | -1.66 | 0.19 | 0.04 | 0.02 | 0.06 | -1.11 |
EBT Excluding Unusual Items | -8.41 | -7.19 | -6.89 | -9.38 | -5.84 | -7.81 |
Asset Writedown | -4.81 | -4.81 | - | - | - | -0.16 |
Other Unusual Items | 4.23 | 4.23 | 1.67 | 0.05 | 0.27 | 0.87 |
Pretax Income | -8.99 | -7.77 | -5.22 | -9.33 | -5.57 | -7.1 |
Income Tax Expense | 0.04 | 0.05 | 0.01 | 0.03 | 0 | 0 |
Net Income | -9.03 | -7.83 | -5.23 | -9.36 | -5.58 | -7.11 |
Net Income to Common | -9.03 | -7.83 | -5.23 | -9.36 | -5.58 | -7.11 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 227 | 227 | 214 | 168 | 90 | 69 |
Shares Outstanding (Diluted) | 227 | 227 | 214 | 168 | 90 | 69 |
Shares Change | 2.00% | 5.82% | 27.89% | 86.08% | 31.20% | 26.95% |
EPS (Basic) | -0.04 | -0.03 | -0.02 | -0.06 | -0.06 | -0.10 |
EPS (Diluted) | -0.04 | -0.03 | -0.02 | -0.06 | -0.06 | -0.10 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -4.49 | -3.87 | -4.72 | -6.72 | -2.13 | -4.1 |
Free Cash Flow Per Share | -0.02 | -0.02 | -0.02 | -0.04 | -0.02 | -0.06 |
Gross Margin | 47.83% | 51.31% | 51.68% | 49.74% | 65.09% | 67.00% |
Operating Margin | -2992.62% | -1636.21% | -510.70% | -2428.48% | -3146.56% | -4207.91% |
Profit Margin | -6074.65% | -3034.00% | -517.47% | -2825.03% | -3661.07% | -5163.23% |
Free Cash Flow Margin | -3020.74% | -1499.59% | -467.79% | -2026.89% | -1399.36% | -2977.84% |
EBITDA | -4.05 | -3.53 | -4.51 | -7.44 | -4.22 | -5.17 |
D&A For EBITDA | 0.41 | 0.69 | 0.65 | 0.61 | 0.58 | 0.63 |
EBIT | -4.45 | -4.22 | -5.16 | -8.05 | -4.79 | -5.79 |